<DOC>
	<DOCNO>NCT00006115</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat patient metastatic colorectal cancer respond previous chemotherapy .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy oxaliplatin , leucovorin calcium , fluorouracil follow irinotecan , leucovorin calcium , fluorouracil term progression free survival patient metastatic colorectal cancer . II . Evaluate treatment regimens term overall survival , response rate , toxicity , quality life patient population . OUTLINE : This multicenter study . Patients receive 4 course oxaliplatin IV leucovorin calcium IV 2 hour day 1 follow fluorouracil IV continuously 46 hour . Following initial 4 course therapy , patient receive 4 course irinotecan IV 30-90 minute leucovorin calcium IV 2 hour day 1 follow fluorouracil IV continuously 46 hour . Courses repeat every 2 week absence disease progression unacceptable toxicity . Quality life assess every 8 week . Patients follow every 3 month death . PROJECTED ACCRUAL : A total 14-39 patient accrue study 12 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic adenocarcinoma colon rectum Measurable evaluable lesion residual disease ( e.g. , ascites , bone metastasis ) Failure first line therapy Fluorouracil leucovorin calcium OR Raltitrexed No oxaliplatin irinotecan Relapse within 6 month adjuvant therapy Relapse within 6 month hepatic artery infusion chemotherapy resect hepatic metastasis No symptomatic brain metastasis PATIENT CHARACTERISTICS : Age : 18 80 Performance status : WHO 02 Life expectancy : At least 3 month Hematopoietic : Absolute neutrophil count least 1,500/mm3 Hepatic : AST ALT great 3 time upper limit normal ( ULN ) Alkaline phosphatase great 5 time ULN Renal : Not specify Other : No bowel obstruction No significant , uncontrolled underlying medical psychiatric condition No serious active infection Neurologically stable No prior malignancy except nonmelanomatous skin cancer carcinoma situ cervix No psychological , social , familial , geographical condition would preclude study Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : At least 2 week since prior radiotherapy Surgery : At least 2 week since prior surgery Other : No concurrent experimental drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2002</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>